Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C–C motif chemokine receptor 6

Published on Apr 30, 2021in Chinese Science Bulletin
· DOI :10.1016/J.SCIB.2020.12.027
Liyuan Jin1
Estimated H-index: 1
(CAS: Chinese Academy of Sciences),
Cao Lei1
Estimated H-index: 1
(Peking Union Medical College Hospital)
+ 5 AuthorsTongbiao Zhao20
Estimated H-index: 20
(CAS: Chinese Academy of Sciences)
Abstract Chimeric antigen receptor-T (CAR-T) cells have limited therapeutic efficacy against solid tumors, partially due to their limited ability to reach and invade into the neoplastic foci. By gene expression profiling interactive analysis, we identified that the C-C motif chemokine ligand (CCL) 20 is highly expressed in lung and other most incidence and/or mortality cancers such as colon, rectum, stomach, and liver cancers. Forced expression of C-C motif chemokine receptor 6 (CCR6), the biunique receptor of CCL20, results in robust trafficking of CAR-T cells toward CCL20-secreting tumor cells. In a lung cancer xenograft mouse model, CCR6-expressing CAR-T cells efficiently migrate to and infiltrate into solid tumors upon infusion, leading to effective tumor clearance and significantly prolonged survival of tumor-bearing mice. In addition, culturing CCR6-CAR-T cells with interleukin (IL)-7 and IL-15 further improved their anti-lung cancer activity. Our findings provide supporting evidence for the clinical development of chemokine receptor-engineered CAR-T cells for solid tumor immunotherapy.
#1Guangna Liu (THU: Tsinghua University)H-Index: 3
#2Wei Rui (THU: Tsinghua University)H-Index: 2
Last. Xin Lin (THU: Tsinghua University)
view all 9 authors...
Unlike hematological malignancies, solid tumors have proved to be less susceptible to chimeric antigen receptor (CAR)-T cell therapy, which is partially caused by reduced accumulation of therapeutic T cells in tumor site. Since efficient trafficking is the precondition and pivotal step for infused CAR-T cells to exhibit their anti-tumor function, strategies are highly needed to improve the trafficking ability of CAR-T cells for solid tumor treatment. Here, based on natural lymphocyte chemotaxis ...
26 CitationsSource
#1Sarwish Rafiq (Emory University)H-Index: 13
#1Sarwish Rafiq (Emory University)H-Index: 3
Last. Renier J. Brentjens (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 63
view all 3 authors...
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven — and impressive — therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with multiple myeloma. Nevertheless, various barriers restrict the efficacy and/or prevent the widespread use of CAR T cell therapies in these patients as well as in those with other cancers, particularly solid tumours. Key challenges relating to CAR ...
173 CitationsSource
#1Jianxia Zhou (CAS: Chinese Academy of Sciences)H-Index: 1
#2Liyuan Jin (CAS: Chinese Academy of Sciences)H-Index: 1
Last. Tongbiao Zhao (CAS: Chinese Academy of Sciences)H-Index: 20
view all 6 authors...
26 CitationsSource
#1Yuan Mao (Nanjing Medical University)H-Index: 9
#2Weifei Fan (Nanjing Medical University)H-Index: 6
Last. Qi Tang (Nanjing Medical University)H-Index: 10
view all 16 authors...
Background Cancer/testis antigens (CTAs) are a special type of tumor antigen and are believed to act as potential targets for cancer immunotherapy.
10 CitationsSource
#1Lars WallstabeH-Index: 3
#2Claudia Göttlich (Fraunhofer Society)H-Index: 5
Last. Michael HudecekH-Index: 27
view all 11 authors...
Solid tumors impose immunologic and physical barriers to the efficacy of chimeric antigen receptor (CAR) T cell therapy that are not reflected in conventional preclinical testing against singularized tumor cells in 2-dimensional culture. Here, we established microphysiologic three-dimensional (3D) lung and breast cancer models that resemble architectural and phenotypical features of primary tumors and evaluated the antitumor function of receptor tyrosine kinase–like orphan receptor 1–specific (R...
42 CitationsSource
#1Linchun Jin (UF: University of Florida)H-Index: 7
#2Haipeng Tao (HMU: Harbin Medical University)H-Index: 3
Last. Jianping Huang (UF: University of Florida)H-Index: 12
view all 20 authors...
Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a result of tumor heterogeneity, immunosuppressive microenvironments, and inadequate intratumoral T cell trafficking and persistence. Early (≤3 days) intratumoral presentation of CAR T cells post-treatment is a superior predictor of survival than peripheral persistence. Therefore, we have co-opted IL-8 release from tumors to enhance intratumoral T-cell trafficking through a CAR design for maximal antitumor act...
64 CitationsSource
#1Lynsey M. Whilding ('KCL': King's College London)H-Index: 13
#2Leena Halim ('KCL': King's College London)H-Index: 4
Last. John MaherH-Index: 33
view all 7 authors...
Despite the unprecedented clinical success of chimeric antigen receptors (CAR) T-cells against haematological malignancy, solid tumors impose a far greater challenge to success. Largely, this stems from an inadequate capacity of CAR T-cells that can traffic and maintain function within a hostile microenvironment. To enhance tumor-directed T-cell trafficking, we have engineered CAR T-cells to acquire heightened responsiveness to interleukin (IL)-8. Circulating IL-8 levels correlate with disease b...
48 CitationsSource
#1Zhao Zhang (Fourth Military Medical University)H-Index: 5
#2Jun Jiang (Beijing Institute of Genomics)H-Index: 5
Last. Zhi-Nan Chen (Fourth Military Medical University)H-Index: 52
view all 10 authors...
Lung cancer is the most common incident cancer and the leading cause of cancer death. In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-T) cell has shown a promising future. Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various types of tumors and has been detected in non-small cell lung cancer with a mutation rate of 10%. Thus, EGFRvIII is a potential antigen for targeted lung cancer therapy. I...
10 CitationsSource
#1Matthew N Metzinger (UT: University of Toledo)H-Index: 1
#2Cherian Verghese (UT: University of Toledo)H-Index: 1
Last. John NemunaitisH-Index: 79
view all 9 authors...
Chimeric antigen receptor (CAR) modified T-cell therapy, a unique platform technology highlighting precision medicine through utilization of molecular biology and cell-based therapeutics has shown unprecedented rates in patients with hematological malignancies such as acute lymphocyte leukemia, non-Hodgkin’s lymphoma and multiple myeloma (MM). With the approval of CD19-targeted CAR T-cells by the Food and Drug Administration in acute lymphoblastic leukemia (ALL) and NHL, this technology is posit...
10 CitationsSource
#1Freddie Bray (IARC: International Agency for Research on Cancer)H-Index: 119
#1Freddie Bray (IARC: International Agency for Research on Cancer)H-Index: 18
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 6 authors...
This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer...
31.7k CitationsSource
Cited By1